I am delighted to announce that this rescheduled zoom session will be taking place at 7.30 pm London time on Monday, the 28th of March. We will be using a Zoom Webinar format instead of a Zoom Meeting to avoid the problems that we had last time. This will be seamless for our participants.
Dr. Jonathan Sackner-Bernstein will be talking to us about: "What If I Discovered the Silver Bullet?"
Motivated by a friend’s suffering from Parkinson’s, Dr. Sackner-Bernstein focused on a gap in our understanding of the disease: no one had so far measured the amount of dopamine in the dopaminergic neurons of people with Parkinson’s. This is critically important because dopamine is toxic to these cells, which would then be a driver of neuron dysfunction and death, leading to disease progression.
He published his analysis last summer in the Journal of Parkinson’s disease showing that these critical neurons do not lack dopamine – they have excess dopamine. This led him to design a clinical trial to test a drug that addresses this newly defined mechanism of disease.
Please see the following article for more information:
prnewswire.com/news-release...
Please use the Eventbrite link below to register for this event:
eventbrite.co.uk/e/dr-sackn...
-----
Dr. Jonathan Sackner-Bernstein was a renowned clinical trialist in cardiology before leaving academics to pursue medical product development, including drug, device and biologic therapeutics.
He served as associate director of the FDA’s device center, where he led diverse programs highlighted by the White House’s first Entrepreneurs-in-Residence program, the Center’s innovation initiative that led to the Breakthrough Devices program and a collaboration between FDA and DARPA to develop systems and products for the Medical Countermeasures Program (focused on responses to chemical, biologic and radiologic mass casualty events).
After serving at the FDA, Dr. Sackner-Bernstein consulted for DARPA, with responsibilities including regulatory strategy and commercial transition of their programs/projects. Jonathan supported the launch of DARPA’s Biological Technologies Office, with a primary focus on neuroscience and big data programs.
Dr. Sackner-Bernstein's academic experience ranges from First-in-Human to international trials, as a clinical investigator and trial leader.
Dr. Jonathan Sackner-Bernstein & Dopamine 
